Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8798MR)

This product GTTS-WQ8798MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8798MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2838MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ11495MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ2124MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALD-403
GTTS-WQ13450MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ11561MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ5901MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ9365MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ1103MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-8E12
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW